These data, relevant to the corresponding disease mechanism in human ALS, suggest that blocking CXCR4 by the small molecule, AMD3100, may provide a novel candidate for ALS therapy with an increased safety. This evidence concerns the gene CXCR4 and amyotrophic lateral sclerosis.